Semaglutide and Tirzepatide “base” (not their salt forms) exist over the FDA drug scarcity record, for that reason compounding pharmacies must not use Semaglutide or Tirzepatide “salt sorts” for compoundingTheir efficacy and security profiles are already proven by means of clinical trials but vary in terms of dosing adaptability and adminis